Physician profile
Stephen E Kessler
NPI 1336671312
$2,124.90
in general payments reported to CMS, 2019-2025
23 companies · $583 in 2025
The $583 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $150 · 2023: $499 · 2024: $893 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,974.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $296.25 | 2022-2025 | |
| Leo Pharma INC. | $263.87 | 2023-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $206.74 | 2022-2025 | Blu-U, Ilumya |
| Regeneron Healthcare Solutions, INC. | $182.28 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $155.03 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $137.34 | 2023-2024 | Sotyktu |
| Janssen Biotech, INC. | $128.96 | 2022-2024 | Tremfya, Stelara, Simponi Aria |
| Dermavant Sciences, INC. | $105.72 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $102.91 | 2024 | |
| Galderma Laboratories, L.P. | $94.46 | 2023-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $77.76 | 2023-2025 | Zoryve |
| Mimedx Group, INC. | $67.04 | 2024-2025 | |
| Biowound Solutions, INC. | $53.73 | 2025 | Bio-Connekt |
| Kyowa Kirin, INC. | $49.99 | 2025 | |
| Organogenesis INC. | $44.67 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $24.54 | 2024 | Bimzelx |
| Mayne Pharma Commercial LLC | $21.55 | 2022 | |
| Biofrontera INC. | $20.00 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.99 | 2024 | Jublia |
| Incyte Corporation | $19.80 | 2023 | Opzelura |
| Surgenex LLC | $18.88 | 2025 | Renograft, Pellograft, Surmatrix |
| Integra Lifesciences Corporation | $17.91 | 2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Lilly USA, LLC | $15.48 | 2023 | Olumiant, Taltz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Kessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.